Gabriel Steg

Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG study

Sardella G, Beerkens F, Dangas G, Cao D, Baber U, Sartori S, Cohen D, Briguori C, Gil R, Nicolas J, Zhang Z, Dudek D, Kunadian V, Kornowski R, Weisz G, Claessen B, Marx S, Escaned J, Huber K, Collier T, Moliterno D, Ohman EM, Krucoff M, Kastrati A, Steg G, Angiolillo D, Mehta SR, Shlofmitz RA, Sharma S, Pocock S, Gibson C, Mehran R

December 2, 2022 | 10.4244/EIJ-D-22-00319

Ticagrelor monotherapy versus aspirin monotherapy at 12 months after percutaneous coronary intervention: a landmark analysis of the GLOBAL LEADERS trial

Ono M, Hara H, Kawashima H, Gao C, Wang R, Wykrzykowska JJ, Piek J, Garg S, Hamm C, Steg G, Valgimigli M, Windecker S, Vranckx P, Onuma Y, Serruys P

August 5, 2022 | 10.4244/EIJ-D-21-00870

Economic evaluation of fractional flow reserve-guided versus angiography-guided multivessel revascularisation in ST-segment elevation myocardial infarction patients in the FLOWER-MI randomised trial

Le Bras A, Puymirat E, Rabetrano H, Cayla G, Simon T, Steg G, Montalescot G, Varenne O, Bonello L, Coste P, Delarche N, Georges J, Chassaing S, Letocart V, Chatellier G, Danchin N, Durand-Zaleski I

June 24, 2022 | 10.4244/EIJ-D-21-00867

Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT study

Dangas G, Baber U, Sharma S, Giustino G, Sartori S, Nicolas J, Goel R, Mehta SR, Cohen D, Angiolillo D, Zhang Z, Camaj A, Cao D, Briguori C, Dudek D, Escaned J, Huber K, Collier T, Kornowski R, Kunadian V, Moliterno D, Ohman EM, Weisz G, Gil R, Krucoff M, Kaul U, Oldroyd K, Sardella G, Shlofmitz RA, Witzenbichler B, Kastrati A, Han Y, Steg G, Pocock S, Gibson CM, Mehran R

March 18, 2022 | 10.4244/EIJ-D-21-00721

Dual antithrombotic therapy with dabigatran in patients with atrial fibrillation after percutaneous coronary intervention for ST-segment elevation myocardial infarction: a post hoc analysis of the randomised RE-DUAL PCI trial

Zeymer U, Leiva O, Hohnloser S, Steg G, Oldgren J, Nickenig G, Gabor Kiss R, Ongen Z, Navarro Estrada J, Oude Ophuis T, Lip G, Nordaby M, Miede C, ten Berg JM, Bhatt D, Cannon C

August 27, 2021 | 10.4244/EIJ-D-20-00799

Ticagrelor alone or conventional dual antiplatelet therapy in patients with stable or acute coronary syndromes

Franzone A, McFadden E, Leonardi S, Piccolo R, Vranckx P, Serruys P, Hamm C, Steg G, Heg D, Branca M, Jüni P, Windecker S, Valgimigli M

October 23, 2020 | 10.4244/EIJ-D-20-00145

Impact of ticagrelor monotherapy on two-year clinical outcomes in patients with long stenting: a post hoc analysis of the GLOBAL LEADERS trial

Takahashi K, Chichareon P, Modolo R, Kogame N, Chang C, Tomaniak M, Moschovitis A, Curzen N, Haude M, Jung W, Holmvang L, Garg S, Tijssen J, Wykrzykowska JJ, de Winter R, Hamm C, Steg G, Stoll H, Onuma Y, Valgimigli M, Vranckx P, Windecker S, Serruys P

October 23, 2020 | 10.4244/EIJ-D-19-00498

Ticagrelor monotherapy beyond one month after PCI in ACS or stable CAD in elderly patients: a pre-specified analysis of the GLOBAL LEADERS trial

Tomaniak M, Chichareon P, Modolo R, Takahashi K, Chang C, Kogame N, Spitzer E, Buszman P, van Geuns R, Valkov V, Steinwender C, Geisler T, Prokopczuk J, Sabaté M, Zmudka K, Rademaker-Havinga T, Tijssen J, Jüni P, Hamm C, Steg G, Onuma Y, Vranckx P, Valgimigli M, Windecker S, Baber U, Anderson R, Dominici M, Serruys P

April 3, 2020 | 10.4244/EIJ-D-19-00699

Patient-oriented composite endpoints and net adverse clinical events with ticagrelor monotherapy following percutaneous coronary intervention: insights from the randomised GLOBAL LEADERS trial

Serruys P, Tomaniak M, Chichareon P, Modolo R, Kogame N, Takahashi K, Chang C, Spitzer E, Walsh S, Adlam D, Hildick-Smith D, Édes I, van de Harst P, Krackhardt F, Tijssen J, Rademaker-Havinga T, Garg S, Steg G, Hamm C, Jüni P, Vranckx P, Onuma Y, Verheugt F

December 20, 2019 | 10.4244/EIJ-D-19-00202

Validation of the updated logistic clinical SYNTAX score for all-cause mortality in the GLOBAL LEADERS trial

Chichareon P, Onuma Y, van Klaveren D, Modolo R, Kogame N, Takahashi K, Chang C, Tomaniak M, Asano T, Katagiri Y, van Geuns R, Bolognese L, Tumscitz C, Vrolix M, Petrov I, Garg S, Naber CK, Sabaté M, Iqbal J, Wykrzykowska JJ, Piek J, Spitzer E, Jüni P, Hamm C, Steg G, Valgimigli M, Vranckx P, Windecker S, Serruys P

August 9, 2019 | 10.4244/EIJ-D-19-00184

Towards Drugs and Devices Synergy. A new session track at EuroPCR: PCR clinical algorithms

Steg G, Wijns W

April 20, 2018 | 10.4244/EIJV13I17A325

Short- and long-term mortality following bleeding events in patients undergoing percutaneous coronary intervention: insights from four validated bleeding scales in the CHAMPION trials

Vaduganathan M, Harrington R, Stone G, Steg G, Gibson CM, Hamm C, Price M, Lopes RD, Leonardi S, Deliargyris E, Prats J, Mahaffey K, White H, Bhatt D

February 2, 2018 | 10.4244/EIJ-D-17-00723

Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial

Vranckx P, Valgimigli M, Windecker S, Steg G, Hamm C, Jüni P, Garcia-Garcia H, Van Es G-A, Serruys P

November 20, 2016 | 10.4244/EIJY15M11_07

Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial

Ducrocq G, Schulte P, Becker R, Cannon C, Harrington R, Held C, Himmelmann A, Lassila R, Storey R, Sorbets E, Wallentin L, Steg G

November 20, 2015 | 10.4244/EIJY14M09_11

Bivalirudin versus unfractionated heparin in percutaneous coronary interventions of patients having received initial fondaparinux treatment: a propensity matched study

Hamon M, Rao SV, Steg G, Valgimigli M, Verheugt F, Marso S, Gershlick A, Wang Y, Deliargyris E

August 24, 2012 | 10.4244/EIJV8I4A76

A simple nomogram for early prediction of myocardial reperfusion after pre-hospital thrombolysis

Rosencher J, Bongard V, Tazarourte K, Soulat L, Savary D, Elbaz M, Miljkovic D, Cottin Y, Lambert Y, Steg G, Puel J, Charpentier S

June 30, 2011 | 10.4244/EIJV7I2A40

Impact of transradial and transfemoral coronary interventions on bleeding and net adverse clinical events in acute coronary syndromes

Hamon M, Mehta SR, Steg G, Faxon D, Kerkar P, Rupprecht H-J, Tanguay J, Afzal R, Yusuf S

May 17, 2011 | 10.4244/EIJV7I1A16

Causes of death in early MI survivors with persistent infarct artery occlusion: results from the Occluded Artery Trial (OAT)

Lang I, Forman S, Maggioni A, Ruzyllo W, Renkin J, Vozzi C, Steg G, Hernandez-Garcia J, Zmudka K, Jimenez-Navarro M, Sopko G, Lamas G, Hochman J

November 15, 2009 | 10.4244/EIJV5I5A98

Stent selection in patients on oral anticoagulants: can we prevent restenosis and avoid bleeding?

Steg G, Ducrocq G

September 30, 2009

Meeting report. ESC Forum on Drug Eluting Stents, European Heart House, Nice, 27-28 September 2007

Daemen J, Simoons M, Wijns W, Bagust A, Bos G, Bowen J, Braunwald E, Camenzind E, Chevalier B, Di Mario C, Fajadet J, Gitt A, Guagliumi G, Hillege H, James S, Jüni P, Kastrati A, Kloth S, Kristensen SD, Krucoff M, Legrand V, Pfisterer M, Rothman M, Serruys P, Silber S, Steg G, Tariah I, Wallentin L, Windecker S

January 20, 2009

Gabriel Steg

Latest news